{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:32:27Z","timestamp":1769725947457,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["APQ-408675\/2018-7"],"award-info":[{"award-number":["APQ-408675\/2018-7"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.cellimm.2020.104194","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T02:18:55Z","timestamp":1597285135000},"page":"104194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis"],"prefix":"10.1016","volume":"356","author":[{"given":"Jo\u00e3o A.","family":"Oliveira-da-Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda S.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda F.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grasiele S.V.","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela P.","family":"Lage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9bora V.C.","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela A.G.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-0457","authenticated-orcid":false,"given":"Tha\u00eds T.O.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edvian T.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00edvia M.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila S.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Ludolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago A.R.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel S.","family":"Bandeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra M.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourena E.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamil S.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana C.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-3263","authenticated-orcid":false,"given":"Bruno M.","family":"Roatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio L.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo A.F.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2020.104194_b0005","doi-asserted-by":"crossref","unstructured":"M.M.C. Abbehusen, J. Cunha, M.S. Suarez, C. Teixeira, V.D.A. Almeida, L.D.S. Pereira, M. Bordoni, L. Gil-Santana, M.D.S. Solc\u00e0, D.B.M. Fraga, L. Fischer, P.T. Bozza, P.S.T. Veras, J.G. Valenzuela, S. Kamhawi, B.B. Andrade, C.I. Brodskyn, Immunization of experimental dogs with salivary proteins from Lutzomyia longipalpis, using dna and recombinant canarypox virus induces immune responses consistent with protection against Leishmania infantum, Front Immunol. 9 (2018) 2558.","DOI":"10.3389\/fimmu.2018.02558"},{"issue":"9","key":"10.1016\/j.cellimm.2020.104194_b0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fimmu.2018.00465","article-title":"New vaccine formulations containing a modified version of the amastigote 2 antigen and the non-virulent Trypanosoma cruzi CL-14 strain are highly antigenic and protective against Leishmania infantum challenge","volume":"15","author":"Almeida","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.cellimm.2020.104194_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cellimm.2020.104194_b0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.molimm.2016.12.022","article-title":"Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in BALB\/c mice","volume":"82","author":"Amit","year":"2017","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2020.104194_b0025","article-title":"A real-time PCR assay for quantification of parasite burden in murine models of leishmaniasis","volume":"9","author":"Antonia","year":"2018","journal-title":"PeerJ"},{"issue":"7","key":"10.1016\/j.cellimm.2020.104194_b0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/17425247.5.7.789","article-title":"Recent developments in leishmaniasis vaccine delivery systems","volume":"5","author":"Bhowmick","year":"2008","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.cellimm.2020.104194_b0035","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1462-5822.2008.01146.x","article-title":"Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example","volume":"10","author":"Bogdan","year":"2008","journal-title":"Cell Microbiol."},{"issue":"8","key":"10.1016\/j.cellimm.2020.104194_b0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3389\/fcimb.2018.00381","article-title":"Cellular markers of active disease and cure in different forms of Leishmania infantum-induced disease","volume":"13","author":"Botana","year":"2018","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"7","key":"10.1016\/j.cellimm.2020.104194_b0045","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Coelho","year":"2003","journal-title":"Infect Immun."},{"key":"10.1016\/j.cellimm.2020.104194_b0050","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2019.00670","article-title":"Cytokines: key determinants of resistance or disease progression in visceral leishmaniasis: opportunities for novel diagnostics and immunotherapy","volume":"10","author":"Dayakar","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2020.104194_b0055","doi-asserted-by":"crossref","unstructured":"M.R. Dikhit, A. Kumar, S. Das, B. Dehury, A.K. Rout, F. Jamal, G.C. Sahoo, R.K. Topno, K. Pandey, V.N.R. Das, S. Bimal, P. Das, Identification of potential MHC class-II-restricted epitopes derived from Leishmania donovani antigens by reverse vaccinology and evaluation of their CD4+ T-cell responsiveness against visceral leishmaniasis. Front Immunol. 8 (2017) 1763. doi: 10.3389\/fimmu.2017.01763.","DOI":"10.3389\/fimmu.2017.01763"},{"key":"10.1016\/j.cellimm.2020.104194_b0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molimm.2016.06.014","article-title":"Coelho EA.A vaccine combining two Leishmania braziliensis proteins offers heterologous protection against Leishmania infantum infection","volume":"76","author":"Duarte","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cellimm.2020.104194_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mib.2012.05.002","article-title":"Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives","volume":"15","author":"Fernandes","year":"2012","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.cellimm.2020.104194_b0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-94-007-7305-9_3","article-title":"A2 and other visceralizing proteins of Leishmania: role in pathogenesis and application for vaccine development","volume":"74","author":"Fernandes","year":"2014","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.cellimm.2020.104194_b0075","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent antimonials: new perspectives for old drugs","volume":"14","author":"Fr\u00e9zard","year":"2009","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.cellimm.2020.104194_b0080","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1172\/JCI116570","article-title":"Reed Interleukin 10 production correlates with pathology in human Leishmania donovani infections","volume":"92","author":"Ghalib","year":"1993","journal-title":"SG J. Clin. Invest."},{"issue":"26","key":"10.1016\/j.cellimm.2020.104194_b0085","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","volume":"34","author":"Gillespie","year":"2016","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.cellimm.2020.104194_b0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/CMR.6.3.230","article-title":"Leishmaniases of the New World: current concepts and implications for future research","volume":"6","author":"Grimaldi","year":"1993","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.cellimm.2020.104194_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185438","article-title":"Field trial of efficacy of the Leish-Tec\u00ae vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates","volume":"12","author":"Grimaldi","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cellimm.2020.104194_b0100","doi-asserted-by":"crossref","unstructured":"S. Gurunathan, L. Stobie, C. Prussin, D.L. Sacks, N. Glaichenhaus, A. Iwasaki, D.J. Fowell, R.M. Locksley, J.T. Chang, C.Y. Wu, R.A. Seder, Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J. Immunol. 165 (2) (2000) 915\u2013924. doi: 10.4049\/jimmunol.165.2.915.","DOI":"10.4049\/jimmunol.165.2.915"},{"issue":"5","key":"10.1016\/j.cellimm.2020.104194_b0105","first-page":"380","article-title":"Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches","volume":"22","author":"Joshi","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2020.104194_b0110","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7555\/JBR.30.20150125","article-title":"Immunogenicity and protective efficacy of DNA vaccine against visceral leishmaniasis in BALB\/c mice","volume":"30","author":"Kaur","year":"2016","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.cellimm.2020.104194_b0115","first-page":"1","article-title":"Immune responses during cutaneous and visceral leishmaniasis","volume":"30","author":"Kedzierski","year":"2014","journal-title":"Parasitology"},{"issue":"5","key":"10.1016\/j.cellimm.2020.104194_b0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/pim.12315","article-title":"DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control","volume":"38","author":"Kumar","year":"2016","journal-title":"Parasite Immunol."},{"issue":"11","key":"10.1016\/j.cellimm.2020.104194_b0125","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1017\/S0031182019000714","article-title":"Screening diagnostic candidates from Leishmania infantum proteins for human visceral leishmaniasis using an immunoproteomics approach","volume":"146","author":"Lage","year":"2019","journal-title":"Parasitology"},{"issue":"3","key":"10.1016\/j.cellimm.2020.104194_b9000","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002148","article-title":"Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis","volume":"7","author":"Martins","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"issue":"1","key":"10.1016\/j.cellimm.2020.104194_b0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vaccine.2009.09.114","article-title":"Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis","volume":"28","author":"Mizbani","year":"2009","journal-title":"Vaccine."},{"issue":"147","key":"10.1016\/j.cellimm.2020.104194_b0135","article-title":"Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis","volume":"30","author":"Oliveira-da-Silva","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.cellimm.2020.104194_b0140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol. Cell Biol."},{"issue":"3","key":"10.1016\/j.cellimm.2020.104194_b0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.imbio.2017.10.043","article-title":"Identification of immune biomarkers related to disease progression and treatment efficacy in human visceral leishmaniasis","volume":"223","author":"Portela","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.cellimm.2020.104194_b0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1631\/jzus.2007.B0153","article-title":"Adjuvant effects of saponins on animal immune responses","volume":"8","author":"Rajput","year":"2007","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.cellimm.2020.104194_b0155","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1016\/j.vaccine.2019.04.092","article-title":"Visceral leishmaniasis: an overview of vaccine adjuvants and their applications","volume":"37","author":"Ratnapriya","year":"2019","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.cellimm.2020.104194_b0160","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.vaccine.2016.03.019","article-title":"Field randomized trial to evaluate the efficacy of the Leish-Tec\u00ae vaccine against canine visceral leishmaniasis in an endemic area of Brazil","volume":"34","author":"Regina-Silva","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.cellimm.2020.104194_b0165","first-page":"1","article-title":"An overview on Leishmania vaccines: a narrative reviewarticle","volume":"6","author":"Rezvan","year":"2015","journal-title":"Vet. Res. Forum"},{"key":"10.1016\/j.cellimm.2020.104194_b0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molimm.2018.12.025","article-title":"Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection","volume":"106","author":"Ribeiro","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cellimm.2020.104194_b0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2018.00018","article-title":"Lipossomal elongation factor-1\u03b1 triggers effector CD4 and CD8 T cells for induction of long-lasting protective immunity against visceral leishmaniasis","volume":"9","author":"Sabur","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2020.104194_b0180","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vetpar.2015.07.005","article-title":"Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis","volume":"212","author":"Shahbazi","year":"2015","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.cellimm.2020.104194_b0185","first-page":"98","article-title":"Recent developments and future prospects in the treatment of visceral leishmaniasis","volume":"3","author":"Sundar","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.cellimm.2020.104194_b0190","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0031182017002116","article-title":"Chemotherapeutics of visceral leishmaniasis: present and future developments","volume":"145","author":"Sundar","year":"2018","journal-title":"Parasitology"},{"issue":"6","key":"10.1016\/j.cellimm.2020.104194_b0195","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.micinf.2017.03.002","article-title":"Bimal Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects. S","volume":"19","author":"Vijayamahantesh","year":"2017","journal-title":"Microbes Infect."},{"key":"10.1016\/j.cellimm.2020.104194_b0200","unstructured":"World Health Organization. Leishmaniasis, 2018. http:\/\/www.who.int\/topics\/leishmaniasis\/en\/."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874920303543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874920303543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T23:04:27Z","timestamp":1757804667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874920303543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":41,"alternative-id":["S0008874920303543"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2020.104194","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2020.104194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104194"}}